

## 2020 STAR Measures Quick Reference Guide (CPT II codes)

<b>3014F</b>	<b>Breast Cancer Screening.</b> Females age 50-74 who had mammogram in the <b>current</b> year or <b>prior</b> year. Screening mammography results documented and reviewed.
<b>3017F</b>	<b>Colorectal Cancer.</b> Colorectal cancer screening results documented and reviewed. <input type="checkbox"/> Colonoscopy in the past 10 years, OR <input type="checkbox"/> Flexible sigmoidoscopy in the past 5 years, OR <input type="checkbox"/> Fecal Occult Blood Test (FOBT) in the current year.
<b>3008F</b>	<b>Adult BMI Assessment.</b> Patients ages 18-74 with BMI documented in the <b>current</b> year or <b>prior</b> year. BMI documented, <b>AND Z68.XX</b> code (ICD 10). <b>Z68.1</b> BMI 19 or less <b>Z68.27</b> BMI 27.0-27.9 <b>Z68.35</b> BMI 35.0-35.9 <b>Z68.44</b> BMI 60.0-69.9 <b>Z68.20</b> BMI 20.0-20.9 <b>Z68.28</b> BMI 28.0-28.9 <b>Z68.36</b> BMI 36.0-36.9 <b>Z68.45</b> BMI <sup>3</sup> 70 <b>Z68.21</b> BMI 21.0-21.9 <b>Z68.29</b> BMI 29.0-29.9 <b>Z68.37</b> BMI 37.0-37.9 <b>Z68.22</b> BMI 22.0-22.9 <b>Z68.30</b> BMI 30.0-30.9 <b>Z68.38</b> BMI 38.0-38.9 <b>Z68.23</b> BMI 23.0-23.9 <b>Z68.31</b> BMI 31.0-31.9 <b>Z68.39</b> BMI 39.0-39.9 <b>Z68.24</b> BMI 24.0-24.9 <b>Z68.32</b> BMI 32.0-32.9 <b>Z68.41</b> BMI 40.0-44.9 <b>Z68.25</b> BMI 25.0-25.9 <b>Z68.33</b> BMI 33.0-33.9 <b>Z68.42</b> BMI 45.0-49.9 <b>Z68.26</b> BMI 26.0-26.9 <b>Z68.34</b> BMI 34.0-34.9 <b>Z68.43</b> BMI 50.0-59.9
<b>1111F</b>	<b>Post-Discharge Medication Reconciliation:</b> Discharge medications reconciled with the current medication list in outpatient medical record with-in 30 days of discharge.
<b>1157F</b> <b>1158F</b>	<b>Advance Care Planning:</b> Patients 66 years of age. ACP present in medical record, <b>OR</b> ACP discussion documented
<b>1159F</b> <b>1160F</b>	<b>Medication Review:</b> Patients 66 years of age whose medication list was Medication list documented, <b>AND</b> Medication list reviewed
<b>1125F</b> <b>1126F</b>	<b>Pain Assessment:</b> Patients 66 years who had pain assessed in the current year. Pain assessed, pain present, <b>OR</b> Pain assessed, no pain present
<b>1170F</b>	<b>Functional Status Assessment (ADLS):</b> Patients 66 years who had functional status assessed in the current year
<b>3095F</b> <b>4005F</b>	<b>Osteoporosis Management in Women who had a Fracture</b> Female patients 67-85 years of age who, within 6 months from a fracture: DEXA results documented, <b>OR</b> Pharmacologic therapy (other than minerals or vitamins) for Osteoporosis prescribed
<b>3044F</b> <b>3051F</b> <b>3052F</b>	<b>*HbA1c Control ≤9%:</b> <u>most recent</u> HbA1C – in MY Most recent HbA1C <7.0% Most recent level greater than or equal to 7.0% and less than 8.0% Most recent level greater than or equal to 8.0% and less than 9.0%

	<p><b>Diabetic Eye Exam:</b> Diabetic patients 18-75 years of age who had a dilated (retinal) eye exam performed in the current year, <b>OR</b> A dilated eye exam with negative for retinopathy in the prior year.</p>
<b>2022F</b>	Dilated retinal eye exam with interpretation by an Ophthalmologist or Optometrist documented and reviewed with evidence of Retinopathy
<b>2023F</b>	Dilated retinal eye exam with interpretation by an Ophthalmologist or Optometrist documented and reviewed without evidence of Retinopathy
<b>2024F</b>	7 standard field stereoscopic retinal photos with interpretation by an Ophthalmologist or Optometrist documented and reviewed with evidence of Retinopathy
<b>2025F</b>	7 standard field stereoscopic retinal photos with interpretation by an Ophthalmologist or Optometrist documented and reviewed with evidence of Retinopathy
<b>2026F</b>	Eye Imaging validation to match diagnosis from 7 standard field stereoscopic retinal photos with interpretation by an Ophthalmologist or Optometrist documented and reviewed with evidence of Retinopathy
<b>2033F</b>	Eye Imaging validation to match diagnosis from 7 standard field stereoscopic retinal photos with interpretation by an Ophthalmologist or Optometrist documented and reviewed <u>without</u> evidence of Retinopathy
<b>3072F</b>	Low risk for retinopathy (negative for retinopathy in the prior year)
	<p><b>Kidney Disease Monitoring:</b> Diabetic patients 18-75 years of age who had medical attention for nephropathy in the current year such as A urine test for Albumin or Protein, <b>OR</b> Documentation of medical attention to nephropathy: visit to nephrologist, treatment of ARF, CKD, ESRD, proteinuria, dialysis, renal transplant., <b>OR</b> An ACE Inhibitor or ARB prescribed.</p>
<b>3060F</b>	Positive microalbuminuria test, <b>OR</b>
<b>3061F</b>	Negative microalbuminuria test, <b>OR</b>
<b>3062F</b>	Positive macroalbuminuria test, <b>OR</b>
<b>3066F</b>	Documentation of treatment for nephropathy, <b>OR</b>
<b>4009F</b>	ACE Inhibitor or ARB prescribed
<b>4187F</b>	<b>Rheumatoid Arthritis Management:</b> DMARD prescribed or dispensed
	<p><b>*Proportion of Days Covered by Medication:</b> Members <math>\geq 18</math>yo who fill their prescription often enough to <b>cover <math>\geq 80\%</math> of the time</b> they are supposed to take the medication.</p> <ul style="list-style-type: none"> <li>✓ <b>Medication Adherence for Diabetes Medications</b> (exclude members using Insulin)</li> <li>✓ <b>Medication Adherence for RAS Antagonists</b></li> <li>✓ <b>Medication Adherence for Statins</b></li> </ul> <p><i>* Please write 90-day supply with 3 refills and please advise your patients to refill their prescriptions!</i></p>

**- Attention -**

*\*Medication Adherence and HBA1C measures are considered triple weighted measures.*